View Exam | PowerPak

1. Monoclonal antibody products are authorized to treat which group of patients with confirmed COVID-19?

A. Any patient B. Any non-hospitalized patient ≥ 18 years of age C. Non-hospitalized patients ≥ 12 years of age at high risk for severe disease D. Patients hospitalized for COVID-19 ≥ 12 years of age requiring oxygen support

2. A 32-year-old patient with T2D and a BMI of 37 has mild COVID-19, with onset of symptoms four days ago. What is the most appropriate management for this patient?

A. Symptom monitoring and home isolation B. Dexamethasone C. Monoclonal antibodies D. Remdesivir

3. According to the ACTT-1 pivotal trial, which group of patients benefited the most from remdesivir?

A. All patients benefitted equally B. Patients not receiving oxygen C. Patients on oxygen not requiring mechanical ventilation or ECMO D. Patients receiving mechanical ventilation or ECMO

4. According to the RECOVERY trial, dexamethasone reduced mortality in all patients with COVID-19 except which group?

A. All patients benefitted equally B. Patients not requiring oxygen C. Patients requiring supplemental oxygen but not ventilated D. Patients requiring ventilation

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Monoclonal antibody products are authorized to treat which group of patients with confirmed COVID-19?

2. A 32-year-old patient with T2D and a BMI of 37 has mild COVID-19, with onset of symptoms four days ago. What is the most appropriate management for this patient?

3. According to the ACTT-1 pivotal trial, which group of patients benefited the most from remdesivir?

4. According to the RECOVERY trial, dexamethasone reduced mortality in all patients with COVID-19 except which group?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Monoclonal antibody products are authorized to treat which group of patients with confirmed COVID-19?

2. A 32-year-old patient with T2D and a BMI of 37 has mild COVID-19, with onset of symptoms four days ago. What is the most appropriate management for this patient?

3. According to the ACTT-1 pivotal trial, which group of patients benefited the most from remdesivir?

4. According to the RECOVERY trial, dexamethasone reduced mortality in all patients with COVID-19 except which group?

« Return to Activity

Customers who Purchased
this Activity also Purchased